Bluejay Therapeutics is a biopharmaceutical company that aims to develop treatments for chronic viral infections and liver disease, particularly chronic hepatitis B virus (HBV) infections. The company has a mission to reduce hepatitis B surface antigen (HBsAg) levels with the goal of restoring antiviral immunity for patients. Bluejay Therapeutics was founded in 2019 by Dr. Keting Chu and is headquartered in San Mateo, CA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
05/09/2024 | Series C-1 | $1.14MM | $xx.xx | $371.77MM | Frazier Life Sciences, RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, Unicorn Capital | |
Price per Share
$xx.xx
Shares Outstanding
173,980
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Frazier Life Sciences, RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, Unicorn Capital
|
||||||
05/09/2024 | Series C | $180.86MM | $xx.xx | $371.77MM | Frazier Life Sciences, RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, Unicorn Capital | |
Price per Share
$xx.xx
Shares Outstanding
27,711,910
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Frazier Life Sciences, RA Capital Management, T. Rowe Price, Wellington Management, Novo Holdings, RiverVest Venture Partners, Octagon Capital, Arkin Bio Ventures, HBM Healthcare Investments, Unicorn Capital
|
||||||
08/16/2022 | Series B | $41MM | $xx.xx | $125.7MM | Arkin Bio Ventures, Synergenics LLC, RiverVest Venture Partners, Yonjin Capital, Octagon Capital, InnoPinnacle International | |
Price per Share
$xx.xx
Shares Outstanding
9,764,218
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Arkin Bio Ventures, Synergenics LLC, RiverVest Venture Partners, Yonjin Capital, Octagon Capital, InnoPinnacle International
|
||||||
06/10/2021 | Series A-1 | $3.37MM | $xx.xx | $48.1MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
910,134
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
1000
Key Investors
Undisclosed Investors
|
||||||
06/10/2021 | Series A | $15.87MM | $xx.xx | $48.1MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
4,293,097
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|